Guide

Medical Foods, Rare Disease and Orphan Supplements: 21 CFR 101.9(j)(8), EU FSMP and Prescriber-Supervised Supply

Medical foods, orphan supplements and rare-disease nutritional therapies operate in a distinct regulatory category separate from dietary supplements. US medical food framework under 21 CFR 101.9(j)(8) and Section 5(b) of the Orphan Drug Act covers products formulated to be consumed or administered enterally under the supervision of a physician, intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements are established by medical evaluation. EU Food for Special Medical Purposes (FSMP) Regulation 609/2013 covers an equivalent category with notification to Member State competent authorities. Inborn errors of metabolism (PKU, MSUD, urea cycle disorders, organic acidemias), chronic kidney disease, cancer cachexia, dysphagia, malabsorption syndromes and selected paediatric conditions drive the medical-food category. This guide covers the US framework, EU FSMP, prescriber-supervised supply, dossier discipline and the supplement-vs-medical-food boundary.

Start free trial Free trial, no credit card, onboard in days, not months.

US medical food framework — 21 CFR 101.9(j)(8) and the four-criteria definition

Medical food is defined under Section 5(b) of the Orphan Drug Act (21 USC 360ee(b)(3)) as a food formulated to be consumed or administered enterally under the supervision of a physician and intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognised scientific principles, are established by medical evaluation. FDA enforcement uses four criteria: (1) the product is specifically formulated to be consumed orally or via enteral feeding tube — not parenteral, not injected, not topical; (2) the product is intended for the specific dietary management of a disease or condition with distinctive nutritional requirements that cannot be met by modification of normal diet alone — the disease-specific nutritional rationale must be documented; (3) the product provides nutritional support specifically modified for the management of the unique nutrient needs that result from the specific disease or condition; (4) the product is used under medical supervision with instructions from a physician on regimen, dose and monitoring. Products failing any criterion are not medical foods — typical failures include conventional food positioning with disease-targeted marketing (not formulated for distinctive nutritional requirements), supplement-positioned products marketed for disease management (no medical supervision), and broad lifestyle health claims (no specific dietary management of a defined disease). Medical foods are exempt from nutrition labelling per 21 CFR 101.9(j)(8) but require ingredient and allergen labelling per 21 CFR 101.4 and 101.62.

EU Food for Special Medical Purposes (FSMP) — Regulation 609/2013

EU Regulation (EU) 609/2013 on food intended for infants and young children, food for special medical purposes and total diet replacement for weight control, with Commission Delegated Regulation (EU) 2016/128 on specific compositional and information requirements for FSMP, establishes the EU medical-food equivalent framework. FSMP is defined as food specially processed or formulated and intended for the dietary management of patients, including infants, to be used under medical supervision, intended for the exclusive or partial feeding of patients with limited, impaired or disturbed capacity to take, digest, absorb, metabolise or excrete ordinary food or certain nutrients contained therein, or with other medically-determined nutrient requirements. FSMP sub-categories include nutritionally complete with standard nutrient formulation, nutritionally complete with nutrient-adapted formulation for specific disease/disorder/medical condition and nutritionally incomplete with standard formulation or nutrient-adapted formulation. FSMP placement on the market requires notification to the Member State competent authority (typical 1-3 month review depending on Member State) with dossier covering composition, intended medical use, nutritional rationale, manufacturer GMP, finished-product specification, stability, labelling and any safety or efficacy evidence. FSMP labelling includes mandatory FSMP designation, statement of use under medical supervision, intended medical use statement and prescribed warning statements. EFSA scientific opinions on specific FSMP nutritional rationales and pre-market evaluation are intermittently required.

Inborn errors of metabolism and the orphan nutritional therapy category

Inborn errors of metabolism (IEM) drive the most distinctive medical-food formulations — phenylketonuria (PKU) requires phenylalanine-restricted protein substitutes; maple syrup urine disease (MSUD) requires branched-chain amino acid-restricted formulations; urea cycle disorders require protein-restricted with conditionally essential amino acid supplementation; organic acidemias (propionic, methylmalonic, isovaleric acidemia) require specific amino acid-restricted formulations; glutaric aciduria type 1 requires lysine and tryptophan restriction; tyrosinaemia requires tyrosine and phenylalanine restriction; long-chain fatty acid oxidation disorders require medium-chain triglyceride substitution. Each IEM formulation is developed against the metabolic defect with disease-specific nutrient composition, validated against the inborn-error metabolic biochemistry and supplied through specialised metabolic dietitian and metabolic physician supervision. Manufacturing requires distinctive amino acid blending, low-protein matrix engineering and specialised paediatric formulation expertise. US regulatory framework treats these as medical foods under 21 CFR 101.9(j)(8) with FDA Orphan Products Grants programme supporting development. EU regulatory framework treats these as FSMP under Regulation 609/2013 with national reimbursement programmes (NHS in UK, statutory health insurance in Germany, France, Italy, Netherlands and Nordic markets) covering specialised metabolic formulations. The newborn screening expansion across major markets has materially expanded the patient population requiring IEM medical food therapy from infancy through adulthood, with growing commercial focus on adolescent and adult IEM formulations addressing lifelong dietary management.

Prescriber-supervised supply, label discipline and the supplement-vs-medical-food boundary

Medical food and FSMP supply operates under prescriber supervision with distinct distribution channels — specialty pharmacy, hospital pharmacy, metabolic clinic pantry programmes and specialty mail-order with prescription verification — rather than the retail or e-commerce channels typical of dietary supplements. Medical-food labelling includes the FDA-required statement 'use under medical supervision' or equivalent, FSMP-required 'use under medical supervision' and intended-medical-use statement, and prescribed warnings. Supplement-vs-medical-food positioning discipline is the dominant recurrent failure mode — products positioned as supplements that meet medical-food criteria (or vice versa) trigger FDA Warning Letters, EU Member State enforcement and reimbursement-programme disqualification. Common failure modes include 'medical-grade' marketing of supplement products to clinical channels (supplement positioning with implied medical-food benefit), low-protein supplement positioning for PKU consumers (medical-food criteria met but supplement marketing avoids regulatory rigor), and adult-onset IEM consumers self-supplying through e-commerce channels without prescriber supervision. The boundary discipline requires per-SKU classification with intended-use evidence chain, distribution-channel control aligned with classification, prescriber-supervision documentation for medical-food products and clear labelling differentiation. Drug positioning is a third boundary — products treating, preventing or curing disease are drugs requiring marketing authorisation regardless of food/supplement/medical-food positioning.

Where this lives in V5 Ultimate

The clauses above aren't theoretical — every one maps to a shipped module and an industry profile. Jump to the parts of the product that turn this guide into evidence on a Monday morning.

Modules that do the work

Document control

Versioned SOPs, controlled artwork, periodic review with e-signatures.

QMS

CAPA, deviations, change control, management review wired together.

Audits & CAPA

Findings auto-route to owners with statutory clocks and evidence trail.

Frequently asked

Is a low-carbohydrate ketogenic formula for diabetes a medical food?

Depends on the four-criteria framework. To qualify as a US medical food under 21 CFR 101.9(j)(8) and Section 5(b) of the Orphan Drug Act: (1) enteral consumption — yes for oral keto formulas; (2) distinctive nutritional requirements established by medical evaluation that cannot be met by modification of normal diet alone — diabetes nutritional management can typically be addressed through normal diet modification, so this criterion is the discriminator; medical-food positioning requires evidence that the specific patient population (e.g. type 2 diabetes with documented diet-modification failure, type 1 with specific metabolic challenges) has distinctive nutritional requirements not addressable through normal diet; (3) formulated for the specific dietary management with disease-specific nutritional rationale; (4) used under medical supervision. Products marketed broadly to diabetes consumers without prescriber supervision and without documented distinctive nutritional requirement evidence are typically not medical foods — they may qualify as conventional foods, dietary supplements with structure/function claims or, if making disease-treatment claims, unauthorised drugs.

What is the difference between US medical food and EU FSMP?

Conceptually similar — both regulate foods specially formulated for dietary management of disease or condition with distinctive nutritional requirements, used under medical supervision. Operationally different. US medical food is defined under 21 CFR 101.9(j)(8) with no FDA pre-market notification required (FDA can challenge classification post-market through Warning Letter enforcement) and no specific compositional requirements beyond the four-criteria framework. EU FSMP under Regulation 609/2013 requires per-product notification to Member State competent authority before placement on market, defined FSMP sub-categories (nutritionally complete standard, nutritionally complete nutrient-adapted, nutritionally incomplete), specific compositional requirements under Delegated Regulation 2016/128, prescribed FSMP labelling and intermittent EFSA evaluation of specific nutritional rationales. Most multinational medical-food brand-owners operate parallel US medical-food and EU FSMP regulatory pathways with market-specific dossier and labelling discipline.

Can we market our medical food directly to consumers through e-commerce?

Generally no for true medical foods — medical food supply operates under prescriber supervision with specialty pharmacy, hospital pharmacy, metabolic clinic pantry programmes and specialty mail-order with prescription verification as the appropriate channels. Direct-to-consumer e-commerce of medical foods without prescriber supervision is a recurrent FDA enforcement target as it undermines the medical-supervision criterion that defines medical-food positioning, potentially reclassifying the product as a dietary supplement (with retroactive compliance failure on supplement framework) or as an unauthorised drug if disease claims are made. Some adult-onset IEM consumers operate self-managed dietary regimens with metabolic dietitian oversight and may obtain medical-food product through specialty mail-order with documentation; direct-to-consumer marketing positioning targeting such consumers requires careful label discipline and channel control to avoid undermining the medical-food classification.

See it on your shop floor.

Free trial, no credit card, onboard in days, not months.

Start free trial See pricing →Browse all resources →